According to Pfizer, the company announced on November 18 an exclusive licensing agreement with Starna Therapeutics granting Pfizer development, manufacturing, and commercialization rights for three in vivo CAR-T programs targeting autoimmune diseases outside Greater China. The agreement includes milestone payments of up to $2.3 billion. The programs are currently in the pre-IND stage.
Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.